Biohaven
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
FDA knocks back Biohaven’s ALS drug over manufacturing concerns
July 22, 2019Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma
Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …
Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial
July 11, 2019Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma
Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …
Reaction mixed to Biohaven’s migraine drug results
March 27, 2018Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical
Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
